Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback